Format

Send to

Choose Destination
J Neurol Sci. 2009 Dec 15;287(1-2):212-5. doi: 10.1016/j.jns.2009.07.021. Epub 2009 Aug 20.

Plasma endocannabinoid levels in multiple sclerosis.

Author information

1
Division of Clinical Neurology at Queens Medical Centre, University of Nottingham, Nottingham NG7 2UH, United Kingdom.

Abstract

BACKGROUND:

Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS. Therapies that affect the endocannabinoid (EC) system may have immunomodulatory, symptomatic and neuroprotective effects.

AIM:

The aim of this study was to determine how levels of EC and related compounds are altered in MS.

METHODS:

Plasma and whole blood were collected from 24 MS patients (10 relapsing-remitting (RR); 8 secondary-progressive (SP); 6 primary-progressive (PP); 19 females; 25-66 years) and 17 controls (10 females; 22-62 years). Plasma EC and related compounds were quantified by liquid chromatography-tandem mass spectrometry. Fatty acid amide hydrolase (FAAH), cannabinoid receptors CB(1) and CB(2) mRNA were measured by quantitative reverse transcriptase-polymerase chain reaction.

RESULTS:

Anandamide (AEA) and palmitoylethanolamide (PEA) were higher in RRMS compared to controls (p=0.001 and p=0.027). AEA, PEA and oleoylethanolamide were also increased in SPMS plasma (p=0.001, p=0.004, and p=0.005). PPMS patients had higher AEA plasma levels compared to controls (p=0.009). FAAH mRNA was decreased in SPMS (p=0.04) but not in RRMS or PPMS blood. CB(1) (p=0.012) and CB(2) mRNA (p=0.003) were increased in the PPMS.

CONCLUSION:

The EC system is altered in MS. It may be dynamically modulated depending on the subtype of the disease, but further studies with larger subgroups are needed to confirm this.

PMID:
19695579
DOI:
10.1016/j.jns.2009.07.021
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center